Ala S, Saeedi M, Ghasemi A, Namdari M, Koulaeinejad N. Effect of atorvastatin 1% mouthwash in the prevention of radiotherapy induced mucositis: A pilot study. Caspian J Intern Med 2022; 13 (4) :800-804
URL:
http://caspjim.com/article-1-2805-en.html
Department of radiology and radiation oncology, Faculty of medicine, Mazandaran University of medical science, Sari, Iran , dr_arash_ghasemi@yahoo.com
Abstract: (3228 Views)
Background: Oral mucositis is a troublesome symptom for people who receive radiotherapy and chemotherapy and it is a dose-dependent factor. Atorvastatin is a HMG-CoA reductase inhibitors and various studies have proven its anti-inflammatory effects. The goal of this study was to evaluate atorvastatin 1% mouthwash effects in prevention of radiotherapy-induced mucositis.
Methods: Atorvastatin 1% suspension was prepared for mouthwash in this randomized, double-blind clinical trial. Thirty patients randomly received atorvastatin or placebo mouthwash. They had to gargle 5cc of mouthwash, 3 times per day during radiotherapy. The severity and pain of mucositis was evaluated every week, during their treatment.
Results: The severity of mucositis between the two study groups was significant every four weeks (p<0.05) and the percentage of patients with more severe mucositis was less in the atorvastatin group. It is found that the pain intensity was lower after 3 and 4 weeks in atorvastatin group.
Conclusion: These findings indicated that atorvastatin mouthwash showed a significant activity in relieving of radiotherapy-induced oral mucositis and pain.
Type of Study:
Short Communication |
Subject:
Oncology Received: 2021/03/13 | Accepted: 2021/09/18 | Published: 2022/09/15